Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 2 Carcinoma, Non-Small-Cell Lung 2 Xanthogranuloma, Juvenile 1 Wilms Tumor 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Neoplasms 1 Multiple Myeloma 1 Medulloblastoma 1 Leukemia, Hairy Cell 1 Histiocytosis, Langerhans-Cell 1 Histiocytic Sarcoma 1 Hepatoblastoma 1 Glioma 1 Ependymoma 1 Central Nervous System Neoplasms 1

Interventions

pembrolizumab 16 Bevacizumab 12 Carboplatin 10 Nivolumab 8 Pemetrexed 7 Temozolomide 6 Standard of Care 6 Exercise 6 Cetuximab 6 durvalumab 5 atezolizumab 5 Prednisone 5 Cyclophosphamide 5 abemaciclib 4 Paclitaxel 4 Doxorubicin 4 Dexamethasone 4 Cisplatin 4 Blood Specimen Collection 4 temsirolimus 3 enzalutamide 3 dostarlimab 3 daratumumab 3 cabozantinib 3 Rituximab 3 Oxaliplatin 3 Metformin 3 Leucovorin 3 Lenalidomide 3 Ipilimumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Vemurafenib × 30 days × Clear all

NCT02693535 2026-05-29

TAPUR

American Society of Clinical Oncology

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡